Overview

Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection

Status:
Withdrawn

Trial end date:
2020-11-20

Target enrollment:

Participant gender:

Summary

The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics. The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.

Phase:

Phase 4

Details

Lead Sponsor:

University Hospital, Limoges

Treatments:

Dexmedetomidine